Sovran Advisors, LLC Galectin Therapeutics Inc Transaction History
Sovran Advisors, LLC
- $770 Billion
- Q1 2025
A detailed history of Sovran Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Sovran Advisors, LLC holds 199,830 shares of GALT stock, worth $267,772. This represents 0.04% of its overall portfolio holdings.
Number of Shares
199,830
Previous 186,014
7.43%
Holding current value
$267,772
Previous $214 Million
28.91%
% of portfolio
0.04%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
112Shares Held
9.91MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.14MShares$2.86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.1 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.58 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.17 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$533,8210.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $79.6M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...